Recursion Pharmaceuticals, Inc.(RXRX)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
RXRX | 1.96 B | - | -60.10% | 0.00% | -$0.97 | -56.58% | 0.07x | 0.00% | $7.18 | $2.77 |
VRTX | 130.44 B | 29.80x | 12.50% | 35.00% | $17.27 | 23.54% | 0.10x | 0.00% | $560.25 | $403.16 |
ALNY | 30.87 B | 38.77x | 66.90% | 16.13% | $5.95 | 96.56% | 2.21x | 0.00% | $495.55 | $197.81 |
ARWR | 8.32 B | - | 171.00% | -47.79% | -$2.29 | -55.21% | 2.96x | 0.00% | $95.49 | $36.57 |
CRSP | 4.82 B | - | 1041.40% | 0.00% | -$4.75 | -26.10% | 0.45x | 0.00% | $75.06 | $44.12 |
NTLA | 1.66 B | - | -46.20% | 0.00% | -$3.22 | -55.44% | 0.10x | 0.00% | $28.25 | $7.95 |
Peer Valuation & Performance Analysis
Peer group analysis for Recursion Pharmaceuticals, Inc. (RXRX) compared to its primary competitors (including VRTX, ALNY, ARWR) reveals distinct metrics. RXRX trades at a valuation discount relative to its competitors, with a P/E ratio of -3.8x versus the peer average of 5.7x (representing a 166% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, RXRX's revenue growth of -60.1% lags behind the peer average of 249.1%, indicating potential market share losses or slower industry adoption. Additionally, its net margin of 0.0% is comparable to the peer average of 0.7%.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• RXRX ranks #0 in P/E ratio, #5 in revenue growth, and #3 in profit margins
• Average ranking: #3 - 📊 Solid financials relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-21 | $3.65 | $3.76 | $3.56 | $3.64 | 19,261,063 | -0.55% |
| 2026-10-20 | $3.56 | $3.67 | $3.47 | $3.66 | 20,925,100 | +1.39% |
| 2026-10-19 | $3.53 | $3.69 | $3.48 | $3.61 | 30,009,600 | +4.18% |
| 2026-10-16 | $4.11 | $4.18 | $3.44 | $3.46 | 40,724,300 | -16.71% |
| 2026-10-15 | $3.65 | $4.41 | $3.53 | $4.16 | 62,870,100 | +11.23% |
| 2026-10-14 | $3.72 | $3.91 | $3.66 | $3.74 | 18,783,700 | -2.48% |
| 2026-10-13 | $4.01 | $4.05 | $3.82 | $3.83 | 19,764,300 | -4.36% |
| 2026-10-12 | $4.31 | $4.37 | $3.91 | $4.01 | 23,785,300 | -8.03% |
| 2026-10-09 | $4.01 | $4.43 | $3.89 | $4.36 | 35,501,300 | +10.38% |
| 2026-10-08 | $4.19 | $4.20 | $3.79 | $3.95 | 30,898,400 | -7.49% |
| 2026-10-07 | $4.50 | $4.60 | $4.23 | $4.27 | 40,730,500 | -7.78% |
| 2026-10-06 | $4.81 | $5.19 | $4.39 | $4.63 | 71,106,000 | -3.14% |
| 2026-10-05 | $4.16 | $4.93 | $4.06 | $4.78 | 67,278,700 | +16.02% |
| 2026-10-02 | $4.18 | $4.27 | $4.01 | $4.12 | 18,840,000 | +1.23% |
| 2026-10-01 | $4.07 | $4.17 | $3.96 | $4.07 | 17,484,100 | -1.45% |
Explore More Analysis for RXRX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.